

1 **Characterising the Disintegration Properties of Tablets in Opaque Media Using Texture**
2 **Analysis**

3

4 Rebekah L. Scheuerle^{a,*}, Stephen E. Gerrard^a, Richard A. Kendall^b, Catherine Tuleu^b, Nigel K. H.
5 Slater^a, Krishnaa T. Mahbubani^a

6

7 ^aDepartment of Chemical Engineering and Biotechnology, BioScience Engineering Research Group,
8 University of Cambridge, New Museums Site, Pembroke Street, Cambridge, CB2 3RA, United
9 Kingdom

10 ^bUniversity College London, School of Pharmacy, Department of Pharmaceutics, London, WC1N 1AX,
11 United Kingdom

12

13 *Corresponding Author:

14 Email: rs765@cam.ac.uk

15 Phone: +44 1223 763 976

16 Address: Department of Chemical Engineering and Biotechnology, BioScience Engineering Research
17 Group, University of Cambridge, New Museums Site, Pembroke Street, Cambridge, CB2 3RA, United
18 Kingdom

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 **Abstract**

35 Tablet disintegration characterisation is used in pharmaceutical research, development, and quality
36 control. Standard methods used to characterise tablet disintegration are often dependent on visual
37 observation in measurement of disintegration times. This presents a challenge for disintegration
38 studies of tablets in opaque, physiologically relevant media that could be useful for tablet
39 formulation optimisation. In this study is explored an application of texture analysis disintegration
40 testing, a non-visual, quantitative means of determining tablet disintegration end point, by analysing
41 the disintegration behaviour of two tablet formulations in opaque media. In this study, the
42 disintegration behaviour of one tablet formulation manufactured in-house, and Sybedia Flashtab
43 placebo tablets in water, bovine, and human milk were characterised. A novel method is presented
44 to characterise the disintegration process and to quantify the disintegration end points of the tablets
45 in various media using load data generated by a texture analyser probe. The disintegration times in
46 the different media were found to be statistically different ($P < 0.0001$) from one another for both
47 tablet formulations using one-way ANOVA. Using the Tukey post-hoc test, the Flashtab placebo
48 tablets were found not to have statistically significant disintegration times from each other in human
49 versus bovine milk (adjusted P value 0.1685).

50 **Key words**

51 Rapidly disintegrating tablet, texture analysis, infant drug delivery, breast milk, Nipple Shield
52 Delivery System, NSDS

53 **Acronyms**

54 Active Pharmaceutical Ingredient (API), Nipple Shield Delivery System (NSDS), United States
55 Pharmacopeia (USP)

56 **1. Introduction**

57 Tablet disintegration properties are characterised during pharmaceutical development to
58 ensure formulation quality following manufacture. Tablet disintegration is also important to
59 characterise because it is a precursor to dissolution (Anwar et al., 2005). Therefore there is a

60 continuing need to characterise tablet disintegration behaviour in vitro to ensure that safe and
61 reliable dosage forms of active pharmaceutical ingredients (APIs) are produced (Donauer and
62 Lobenberg, 2007).

63 Conventional tablet disintegration is characterised using methods harmonised across the
64 U.S. Pharmacopeia (USP), the European Pharmacopoeia, and the Japanese Pharmacopeia. As
65 described by the USP, to perform the disintegration test, tablets are placed in the USP Apparatus A
66 within a basket-rack assembly, churned in water, and visually examined to determine disintegration
67 completion (U.S. Pharmacopeial Convention, 2014a). In this method tablet disintegration is defined
68 as complete when the tablet appears to have no palpable firm core (U.S. Pharmacopeial Convention,
69 2014a). The standard method of visual discernment to assess tablet disintegration time could be
70 complemented with additional quantitative measurement techniques, to aid understanding of tablet
71 disintegration behaviour. This is especially true for fast release formulations, such as rapidly
72 disintegrating tablets, whose high speed of disintegration make visual assessment of disintegration
73 using the USP apparatus challenging. Currently there is no designated method of disintegration
74 characterisation specifically for rapidly disintegrating tablets in any of the three mentioned
75 pharmacopoeias (U.S. Pharmacopeial Convention, 2014a).

76 Experimental quantitative methods for the characterisation of tablet disintegration time has
77 been developed using a texture analyser (Dor and Fix, 2000)(el-Arini and Clas, 2002)(Szakonyi and
78 Zelkó, 2013). Disintegration testing via texture analysis could be broadly beneficial for disintegration
79 testing in opaque media since the technique does not require visually assessing completion of tablet
80 disintegration. Developing quantitative methods for disintegration testing of tablets in opaque
81 media, such as milk and other mixtures present in the digestive system, could further support
82 existing tablet disintegration characterisation methods. This data could be useful for optimising
83 tablet formulations, like those designed to disintegrate in milks, juices, or other opaque media prior
84 to administration. In the described study, texture analysis is used for a novel application, specifically
85 as a method to quantify disintegration time in opaque media. The specific application of developing

86 rapidly disintegrating and dispersible tablets to be used in a novel breast milk mediated drug
87 delivery system for infants is used as an example for the usefulness of this technique.

88 During texture analysis disintegration testing, a probe is lowered against a disintegrating
89 tablet in a liquid. In one method, the probe applies a constant load to the tablet and moves at a
90 variable velocity. In another method, the probe moves at a constant velocity while applying a
91 variable load to the tablet. In the constant load technique, the distance travelled by the probe as
92 the tablet disintegrates is recorded (Abdelbary et al., 2005). In the constant velocity technique, a
93 load-displacement curve is generated, from which the in vivo disintegration times have been
94 predicted from an empirical equation (Szakonyi and Zelkó, 2013). Both methods have shown positive
95 correlation with in vivo data (Abdelbary et al., 2005) (Dor and Fix, 2000) (Szakonyi and Zelkó, 2013).
96 In this study, the constant load technique is used to characterize tablet disintegration in opaque
97 media.

98 Rapidly disintegrating tablets, also known as fast disintegrating or orally disintegrating
99 tablets, have formulations designed to disintegrate entirely in the mouth prior to swallowing. These
100 tablets are defined by their administration method rather than by a disintegration time specification
101 (U.S. Department of Health and Human Services, 2008). Additionally, dispersible tablets, which are
102 administered after dispersion in liquids such as water or milk, also have very fast disintegration
103 times, typically less than 3 min (UNICEF, 2013). There is therefore high patient compliance
104 associated with the administration of rapidly disintegrating and dispersible tablets to children,
105 elderly, and those with dysphagia because they reduce administration complications for populations
106 with difficulty swallowing (Fu et al., 2004).

107 An administration method for delivering rapidly disintegrating and dispersible tablets
108 specifically to infants has been proposed using a novel Nipple Shield Delivery System (NSDS)
109 (Gerrard, Larson, et al., 2013) (Gerrard, Orlu-Gul, et al., 2013) (Hart et al., 2014) (Sokal et al., 2013).
110 When worn by a mother during breastfeeding, an insert, such as a tablet, is held within the NSDS

111 and releases an API into breast milk consumed by the infant (Gerrard, Orlu-Gul, et al., 2013) (see
112 Figure 1).

113 The NSDS could potentially provide a simple method for infant drug delivery and a hygienic
114 and natural means of administering medications to infants. To understand the dosing and drug
115 delivery of potential tablet formulations using the device, their disintegration behaviour in human
116 milk needs to be characterised. A critical design specification for tablets used in the NSDS is that the
117 entirety of the API is released into the breast milk within one breastfeed; therefore, disintegration
118 characterisation of the tablets is especially important.

119 Characterisation of tablet disintegration in human milk via texture analysis provides a novel
120 method of screening potential tablet formulations for the NSDS. In addition, disintegration testing in
121 bovine milk serving as a fed-state gastric fluid model (Anwar et al., 2005) could prove widely
122 applicable in pharmaceutical development.

123 **2. Materials and methods**

124 Characterisation of tablet disintegration was performed through analysis of position and
125 load data of a texture analyser probe applying constant load to tablets disintegrating in various
126 media.

127 **2.1 Media**

128 Disintegration was characterised in a variety of media including deionised water, human
129 milk, and bovine milk. The three media used in the study were chosen due to their relevance in
130 previous disintegration characterisation literature and their applications in facilitating tablet
131 disintegration in numerous applications.

132 Water was selected because it is the media used in USP disintegration characterisation, and
133 has been used in the literature for texture analysis disintegration testing previously (Abdelbary et al.,
134 2005)(Dor and Fix, 2000). It is frequently used to dissolve and disintegrate tablets in a variety of
135 applications including drug delivery, by facilitating reconstitution of dispersible tablets prior to
136 administration.

137 Human milk was selected because thorough understanding of tablet disintegration
138 behaviour in this fluid is critical to formulation development of tablets to be used in the NSDS. Other
139 methods of characterising tablet disintegration behaviour in human milk is challenging since human
140 milk is not transparent, obstructing visual observation. Therefore, to determine if texture analysis
141 could be applied to screening tablets for development of dosage formulations appropriate for the
142 NSDS, human milk was tested as one of the media.

143 The human milk was obtained from 10 healthy donors (screened negative for HIV 1 and 2,
144 HTLV I and II, Hepatitis B and C, and Syphilis) who had consented for their milk to be used for
145 research. The Cambridge Human Biology Research Ethics Committee at the University of Cambridge
146 provided ethical approval for all human milk sample use. All of the milk was centrifuged (Sigma-
147 Zentrifugen, Osterode, Germany) for 15 min at 5500 RPM, from which the fat later was removed and
148 into which the protein layer was resuspended to produce fat-free milk. Milk batches of various fat
149 compositions were produced through mixing various proportions of fat and fat-free milk, from which
150 one composition was selected for use in this study (3.4 wt% fat, 1.8 wt% protein, Queen Charlotte's
151 and Chelsea Hospital Milk Bank). Protein content was measured using a standard Bradford Agent
152 (Sigma Aldrich, Dorset, UK) assay (Bradford, 1976).

153 Human milk fat content is highly variable, with average fat content varying between
154 colostrum, transitional, and mature milk. The averages range from 2.6 w/v% to 4.1 w/v% depending
155 on the time of day, the number of days post-partum, the time within the feed, and the mother
156 (Emmett and Rogers, 1997). The composition of human milk for the study was chosen such that the
157 fat content fell within this physiologically relevant range. Prior to the experiments, the human milk
158 was thawed from -80 °C storage in a 3 °C refrigerator for 2 days.

159 The human milk fat content was calculated based on creatocrit measurements performed
160 on 1 mL milk samples centrifuged (Sigma-Zentrifugen) for 15 min in 4.6 mm inner diameter, 80 mm
161 length tubes at 930g. Creamatocrit values were used in Wang et al.'s creatocrit to fat correlation
162 for thawed samples stored at -20 °C (Wang et al., 1999). The milk was thawed from -80 °C and this

163 correlation is assumed to adequately assess fat content for these conditions (Gerrard, Orlu-Gul, et
164 al., 2013).

165 Bovine milk, a fluid which has been used to simulate fed-state stomachs in the literature
166 (Jantratid et al., 2008), was selected because fluid conditions in the stomach are important to
167 consider for characterisation of tablet medications which are swallowed whole and intended to
168 disintegrate in the stomach. Like human milk, bovine milk, being opaque, is also challenging when
169 used in disintegration characterisation methods which rely on visual observation. Therefore texture
170 analysis testing, by providing an analytical method of determining disintegration end points, is
171 advantageous for this fluid.

172 The bovine milk used in the study was pasteurised, homogenised, bovine milk (Whole Cow
173 Milk, 4 w/v% fat, 3.3 w/v% protein, J.S. Sainsbury's, Cambridge, UK), which was thawed from -80 °C
174 storage in a 3 °C refrigerator for 2 days prior to use.

175 **2.2 Tablet formulation**

176 Commercial grade as well as tablets manufactured in-house were characterised. Sybedia
177 Flashtab placebo biconcave tablets with a proprietary composition were supplied by Ethypharm (Le
178 Grand Quevilly Cedex, France). Biconcave directly compressed tablets containing Sulforhodamine B,
179 hereafter referred to as SRB tablets, were formulated in-house using the components listed in Table
180 1. The SRB tablet excipients were chosen based on pre-existing formulations for rapidly
181 disintegrating tablets (Charoo et al., 2012). These tablets serve as model tablets for NSDS
182 development.

183 The SRB tablets were formulated by initially blending the filler, model compound, and
184 superdisintegrants, followed by blending in the lubricant, sieving at 500 µm, and blending a final
185 time. The powder blend was directly compressed using a Manesty F3 tablet press (Manesty,
186 Liverpool, UK) with a biconvex 80 single punch and die set (Holland, Nottingham, UK).

187 **2.3 USP characterisation of tablets**

188 All tablets were physically characterised using USP methods, aside from the modification
189 that disintegration testing was performed individually on each tablet rather than in a set of six. This
190 modification to the USP method allowed more accurate discernment of the standard deviation of
191 the average disintegration time since the tablets disintegrate so rapidly. This disintegration testing
192 was performed using a disintegration apparatus with a basket rack assembly (Copley, Nottingham,
193 UK). Tablet length, width, and height were measured using calipers. Crushing force was tested using
194 an Erweka TBH200 hardness tester (Heusenstamm, Germany) with the tablets oriented
195 diametrically. Physical characterisation data are shown in Table 2.

196 **2.4 Texture analysis characterisation method**

197 Texture analysis disintegration characterisation was performed using a TA.XT*plus* Texture
198 Analyser (Stable Microsystems Ltd., UK) equipped with a 14.23 mm diameter probe set to maintain a
199 constant load of 50g. The load value chosen was found to sufficiently hold the tablets in place during
200 each experiment, and has been used in other texture analysis studies (Abdelbary et al., 2005).
201 Exponent Software (Stable Microsystems Ltd., UK) was used to monitor the probe lowering distance
202 and applied load over time as each tablet disintegrated.

203 During each test, a tablet was attached vertically to the probe using double-stick tape
204 (Sellotape, Winsford, UK). This tablet orientation served to increase the surface area of tablet
205 exposed to media when compared to the horizontal tablet orientation used in other studies
206 (Abdelbary et al., 2005) (Dor and Fix, 2000) (Szakonyi and Zelkó, 2013) so as to more accurately
207 represent the orientation of a tablet during use in a NSDS. Upon probe lowering, the tablet was
208 immersed into 31 mL of media pre-heated to 37 °C using a hot plate (Gallenkamp, UK) in a 50 mL
209 beaker. Immediately before experiments commenced, the beaker was moved to the texture
210 analyser held at laboratory temperature, resulting in a media temperature always above 32°C
211 throughout the experiments. This temperature range includes the range of temperature of artificial
212 saliva mimicked in a previous texture analysis study (Abdelbary et al., 2005) and is relevant to the
213 physiological temperature range of human milk in the NSDS. Media volume was chosen to ensure

214 complete tablet immersion in the beaker. The platform contained concentric holes to minimize
215 accumulation of disintegrated tablet material during testing and therefore more closely mimic the
216 removal of disintegrated tablet that would occur in vivo or during delivery using the NSDS. The hole
217 diameter and spacing was chosen based on ease of manufacture. The centre of the platform
218 remained non-perforated to prevent the tablet from being pressed through the platform by the
219 probe during testing. A diagram of the apparatus is shown in Figure 2.

220 Statistical analysis of the results was performed using GraphPad Prism (La Jolla, California,
221 USA).

222 **3 Results and discussion**

223 **3.1 Disintegration characterisation analysis method**

224 Two sets of data over time were collected during the experiments including the texture
225 analyser probe's vertical movement and the applied load by the probe. These data profiles were
226 compared against each other in post-experimental analysis.

227 Three regions of the probe distance-time profile have been previously defined in the
228 literature, termed the initial region (I), the ascending region (A), and the plateau region (P) as
229 designated in Figure 3 (Abdelbary et al., 2005) (el-Arini and Clas, 2002). Previous studies have shown
230 one ascending and one plateau region per tablet tested. In these previous studies, the critical point
231 between the ascending and plateau region was defined as the termination of disintegration and
232 used to calculate the onset of disintegration. This was based on extrapolation from the slope of the
233 ascending region (Dor and Fix, 2000). At that critical time point, the probe plateaued because it
234 could lower no further due to resistance from the platform.

235 Probe load was maintained over all time apart from when the load measured decreased
236 momentarily when the tablet integrity was compromised. These local load minima were due to
237 inherent lags in the feedback response of the system to changes in the tablet structure as
238 disintegration occurred. The load then returned to the set value (as the probe moved further down
239 into the beaker). This was due to resistance from the remaining portion of tablet being detected in

240 the load feedback loop used by the texture analysis software. When the load applied by the probe
241 was superimposed over the position data over time it became evident that load minima occur during
242 time frames of increased probe movement rate.

243 As with the USP disintegration experimental method, it was hypothesised that tablet
244 disintegration commenced from the moment of tablet contact with the media. Specifically for the
245 described method, tablet disintegration was considered to likely be occurring during the initial
246 region (I) due to mechanisms such as dissolution and material loss following tablet hydration. The
247 ascending region, labelled A in Figure 3, was then assumed to occur due to substantial tablet
248 fracture. This assumption was supported by load data, which indicated that there was a loss in tablet
249 integrity to resist the probe in this region. This drop in load would be expected from a sudden
250 change in tablet morphology such as tablet fracturing.

251 In some cases there were multiple ascending and plateau regions, as shown in Figure 4. The
252 detected local load minima in the ascending regions were hypothesised to indicate partial fracturing
253 of the tablet. This was hypothesised because maintenance of constant load would be expected to be
254 compromised due to sudden changes in the tablet owing to cracking. Following partial tablet
255 cracking the probe then regained the specified load against the remaining tablet core, causing a
256 plateau region. This observation suggests that partial disintegration of tablets and therefore tablet
257 structure can be quantifiably characterised using this previously unstudied novel method.

258 Since a disintegrated tablet is defined according to the USP 37 (U.S. Pharmacopeial
259 Convention, 2014a) by a lack of palpable core, tablet disintegration could therefore be defined as
260 complete at the time point corresponding to the local load minima within the final ascending region
261 (A). This is the time point at which the last remaining remnant of tablet core has been compromised.

262 The final plateau then corresponded to the probe pressing down on remaining disintegrated
263 tablet and the platform. Total disintegration time was calculated by summing the time from the
264 initiation of the initial region to the disintegration end-point with the time over which the tablet was
265 lowered into the media. The tablet lowering time, beginning with tablet to media contact, was

266 calculated using the height of the media above the platform and the speed of the probe as the tablet
267 lowered. In this study, the lowering time was 2.6s. This value could be changed through
268 manipulation of opaque media volume, beaker size, or platform height in future studies to study the
269 impact on tablet disintegration. To our knowledge, this method is the first to use both position and
270 load data in this way to identify absolute end points for disintegration.

271 **3.2 Results of texture analysis disintegration characterisation using various media**

272 Probe position data resulting from the texture analysis study of the SRB tablets and Flashtab
273 placebo tablets in water, bovine milk, and human milk differ as shown in Figure 5. The tablet
274 disintegration times, as identified using the described load data method, for which white markers
275 are shown in Figure 5, are listed in Table 2.

276 During experimentation, it was expected that after the first observed ascending region,
277 tablet disintegration would be complete, but further data analysis and longer experimental data
278 collection demonstrated that the assumed palpable core was still present in many cases afterwards.
279 This could be discerned by observing the total change in probe distance, which should be close to
280 but not equal to the diameter of the tablet. The probe was not expected to move the entire tablet
281 diameter distance because broken up tablet material remains at the end of testing preventing probe
282 contact with the platform. It should be noted that this strategy of observing total probe movement
283 can be used in order to assess completion of testing in future studies. Data sets for which complete
284 disintegration did not occur were not analysed in this study, leading to varying sample sizes.

285 One Ethypharm Flashtab placebo tablet disintegrating in bovine milk as well as one in human
286 milk stand out as having different position-time profiles than the others, as shown in Figure 5. These
287 tablets are believed to have undergone disintegration in a different way than in the other tablets,
288 potentially due to inherent internal or structural weaknesses leading to more large fractures, as
289 suggested by the multiple ascending and plateau regions. These differences are clear using the
290 texture analysis data, and provide additional understanding of disintegration behaviour to what

291 potentially would be observed using USP testing. This is hypothesised because the behaviour is
292 identified before complete disintegration, the parameter tested in the USP method.

293 Considering that all tablets disintegrated within 6 min using the texture analyser, this
294 method has demonstrated itself to be a comparable method to assess tablet disintegration
295 behaviour to USP testing in terms of time-burden. Since each tablet must be tested individually
296 though, this method takes more time than the USP method, in which six tablets are typically tested
297 in parallel (U.S. Pharmacopeial Convention, 2014a).

298 In general, the SRB tablets disintegrated in a longer time frame than the Flashtab placebo
299 tablets, and showed variability in repeat testing for various media types. This is likely due to
300 compositional, geometry, size, surface area, and manufacturing method formulation differences
301 between the tablets resulting in varying pore structures and tablet disintegration characteristics.
302 Future testing would be necessary to determine the main cause of variability.

303 Based on one-way ANOVA, the disintegration time of the SRB tablets in the different media
304 were found to be significantly different ($P < 0.0001$), as were those for the Flashtab Placebo tablets
305 ($P < 0.0001$). Based on the Tukey multiple comparisons test, the SRB tablets and Flashtab Placebo
306 tablets disintegration times were each statistically different in each milk compared to water,
307 disintegrating faster in water (adjusted P value < 0.0001 for both tablets). Based on this test, the
308 disintegration time of the SRB tablets in each milk media were significantly different from one
309 another also (adjusted P value < 0.0001), disintegrating faster in human milk than bovine milk. The
310 Tukey multiple comparisons test indicated that the Flashtab Placebo tablets had no significant
311 difference between the disintegration times for the two milk media (adjusted P value = 0.1685). For
312 each condition, the standard deviation of the average disintegration time was relatively small,
313 indicating robustness of the method for reproducibly determining tablet disintegration times.

314 Differences in media viscosity, surface tension, and composition, as well as contact angle to
315 the tablet are likely dominating factors in influencing tablet disintegration due to their influence on
316 liquid penetration rates into the tablet (Abrahamsson et al., 2004) (Anwar et al., 2005). Tablets have

317 been shown to disintegrate slower in bovine milk than in water due to higher viscosity and lower
318 surface tension that cause a decrease in liquid penetration rate, preventing wetting (Anwar et al,
319 2005). Whereas the viscosity of water and bovine milk is different (reported as 0.6915 mPa·s and 1.3
320 mPa·s, respectively) (Anwar et al, 2005), that of bovine and human milk (averaging 1.35 mPa·s - 1.5
321 mPa·s) is less so (McDaniel et al., 1989). This suggests viscosity may not be the main cause for the
322 differing disintegration times of the SRB tablets between each milk media. Compositional differences
323 between the media may have led to differing tablet disintegration times. Protein presence in media
324 has been shown to have a large effect on tablet disintegration time due to protein and carbohydrate
325 film formation on the tablets preventing liquid penetration (Abrahamsson et al, 2004). Protein
326 concentration in the human and bovine milk differed (being 1.8 wt% and 3.3 w/v%, respectively),
327 which may have caused differing film formation on the SRB tablets, resulting in differing tablet
328 disintegration times. It is noted that fat content of the media, being 3.4 wt% for the human milk and
329 4 w/v% for bovine milk, were similar, and so are unlikely to be a main cause of tablet disintegration
330 time variability.

331 Future studies assessing tablet disintegration in various other opaque media using texture
332 analysis could be performed, such as fruit juices or other solutions to which tablets used as
333 medicines, vitamins, minerals, or flavour enhancers are added. Studies which assess the impact of
334 manufacturing processes on tablet solid fraction and the resulting tablet disintegration time
335 uniformity could also be completed. These studies could be valuable in setting manufacturing
336 specifications such as tableting compression values. Disintegration testing in opaque media could
337 have wider implications outside of pharmaceutical commercialisation as well, such as for
338 characterisation of tablets added to opaque emulsions, solutions, or mixtures in commercial
339 processes. Additionally, texture analysis testing of tablets in mixing liquids could be performed to
340 understand how media movement impacts tablet disintegration. These tests may serve to mimic the
341 solution movement which may be present during various tablet disintegration processes, such as the

342 stirring of a media to which a tablet has been added, or the churning of the stomach into which a
343 tablet enters.

344 **4 Conclusion**

345 Assessment of tablet disintegration properties has been shown possible in opaque fluids
346 using texture analysis disintegration testing. This technique allows for quantitative determination of
347 disintegration end point times independent of observation. This is especially beneficial for
348 characterising disintegration of rapidly disintegrating and dispersible tablets, for which
349 characterisation can be challenging due to the fast speed at which the tablets disintegrate
350 complicating visual discernment of disintegration completion end point times in the USP method.
351 Additionally, this study demonstrates a novel analytical method of assessing data collected in the
352 constant load texture analysis method. In this method, load data is shown to be useful for
353 characterisation of tablet fracturing behaviour prior to complete tablet disintegration, a phenomena
354 which is not quantitatively measurable using USP methods. By identifying time points corresponding
355 to local probe load minima during the constant load texture analysis technique, corresponding
356 hypothesised instances of tablet fracture are identified. Final tablet disintegration is then defined as
357 complete following the time point corresponding to the final tablet fracture.

358 The results of the study have shown texture analysis could be useful in further characterising
359 the disintegration behaviour in human milk of potential tablet formulations for use in a nipple shield
360 delivery system, a novel method for delivery of life-saving medications or nutrients to breastfeeding
361 infants. Various supplemental or therapeutic tablet formulations could be studied in human milk
362 with compositions ranging in fat and protein content to robustly characterise potential formulations
363 in the range of conditions which may be present resulting from breastfeeding. Additionally, this
364 texture analysis method could allow for characterisation of tablet formulations in opaque media for
365 other commercial development purposes. Generally, this method could be used to assess the
366 likelihood of internal tablet fracture resulting from various tablet manufacturing methods. This
367 information could be used to define tablet solid fraction specifications and corresponding tablet

368 manufacturing process specifications. Further method development studies could also be performed
369 to determine how load induced by the probe during testing may impact tablet disintegration
370 uniformity for tablets in the presented vertical orientation, as has been performed with tablets
371 placed horizontally in other texture analysis studies (Dor and Fix, 2000).

372 **Acknowledgements**

373 This work was made possible through the generous support of the Saving Lives at Birth
374 partners: the United States Agency for International Development (USAID), the Government of
375 Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada and the UK Department for
376 International Development (DFID); as well as the Gates Cambridge Trust. Ethypharm is also thanked
377 for the donation of the Sybedia Flashtab placebo tablets used in the study.

378 Gillian Weaver, manager of the Queen Charlotte's and Chelsea Hospital Milk Bank is also
379 thanked (Imperial College Healthcare NHS Trust) for coordinating use of human milk samples.

380 Additional thanks goes out to Gary Chapman, workshop technician in the University of
381 Cambridge Chemical Engineering and Biotechnology workshop, for building the platform used in this
382 study.

383 Laura MacBean and Dhruvkumar Patel are thanked for providing information about how
384 tablet disintegration is effected by disintegration media composition and viscosity. Thanks also goes
385 to Aspen Flynn for editing the manuscript.

386 Stephen Gerrard is an inventor of the nipple shield delivery system (US patent 8357117 B2
387 and patent pending PCT/US10/44589, see <http://justmilk.org>).

388 **References**

389 Abdelbary, G., Euoani, C., Prinderre, P., Joachim, J., Reynier, J., & Piccerelle, P. (2005). Determination
390 of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral
391 disintegration. *Int. J. of Pharm.*, 292, 29–41. doi:10.10106/j.ijpharm.2004.08.019

392 Abrahamsson, B., Albery, T., Eriksson, A., Gustafsson, I., & Sjoberg, M. (2004). Food effects on tablet
393 disintegration. *Eur. J. of Pharm. Sci.*, 22(2-3), 165-72. doi:10.1016/j.ejps.2004.03.004

- 394 Anwar, S., Fell, J. T., & Dickinson, P. A. (2005). An investigation of the disintegration of tablets in
395 biorelevant media. *Int. J. of Pharm.*, 290(1-2), 121–7. doi:10.1016/j.ijpharm.2004.11.023
- 396 Bradford, M. M., (1976). A rapid and sensitive method for the quantitation of microgram quantities of
397 protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72(1), 248-254.
- 398 Charoo, N. a, Shamsheer, A. a a, Zidan, A. S., & Rahman, Z. (2012). Quality by design approach for
399 formulation development: a case study of dispersible tablets. *Int. J. of Pharm.*, 423(2), 167–78.
400 doi:10.1016/j.ijpharm.2011.12.024
- 401 Donauer, N., & Lobenberg, R. (2007). A mini review of scientific and pharmacopeial requirements for
402 the disintegration test. *Int. J. of Pharm.*, 345(1-2), 2–8. doi:10.1016/j.ijpharm.2007.08.045
- 403 Dor, P. J. M., & Fix, J. A. (2000). In Vitro Determination of Disintegration Time of Quick-Dissolve
404 Tablets Using a New Method. *Pharm. Dev. and Technol.*, 5(4), 575–577.
405 doi:10.1081/PDT100102041
- 406 el-Arini, S. K., & Clas, S.-D. (2002). Evaluation of disintegration testing of different fast dissolving
407 tablets using the texture analyzer. *Pharm. Dev. and Technol.*, 7(3), 361–71. doi:10.1081/PDT-
408 120005732
- 409 Emmett, P. M., & Rogers, I. S. (1997). Properties of human milk and their relationship with maternal
410 nutrition. *Early Hum. Dev.*, 49 Suppl, S7–28. doi:10.1016/S0378-3782(97)00051-0
- 411 Fu, Y., Yang, S., Jeong, S. H., Kimura, S., & Park, K. (2004). Orally Fast Disintegrating Tablets :
412 Developments , Technologies , Taste-Masking and Clinical Studies. *Crit. Rev. in Ther. Drug Carr.*
413 *Syst.*, 21(6), 433–475.
- 414 Gerrard, S. E., Larson, A. M., Klibanov, A. M., Slater, N. K. H., Hanson, C. V, Abrams, B. F., & Morris,
415 M. K. (2013). Reducing infectivity of HIV upon exposure to surfaces coated with N,N-dodecyl,
416 methyl-polyethylenimine. *Biotech. and Bioeng.*, 110(7), 2058–62. doi:10.1002/bit.24867
- 417 Gerrard, S. E., Orlu-Gul, M., Tuleu, C., & Slater, N. K. H. (2013). Modeling the physiological factors
418 that affect drug delivery from a nipple shield delivery system to breastfeeding infants. *J. of*
419 *Pharm. Sci.*, 102(10), 3773–83. doi:10.1002/jps.23688
- 420 Hart, C. W., Israel-Ballard, K. a, Joanis, C. L., Baniecki, M. L., Thungu, F., Gerrard, S. E., ... Sokal, D. C.
421 (2015). Acceptability of a Nipple Shield Delivery System Administering Antiviral Agents to
422 Prevent Mother-to-Child Transmission of HIV through Breastfeeding. *J. of Hum. Lact.*, 31(1):68-
423 75 doi:10.1177/0890334414559980
- 424 Jantratid, E., Janssen, N., Reppas, C., & Dressman, J. B. (2008). Dissolution media simulating
425 conditions in the proximal human gastrointestinal tract: an update. *Pharm. Res.*, 25(7), 1663–
426 76. doi:10.1007/s11095-008-9569-4
- 427 McDaniel, M. R., Barker, E., & Lederer, C. L., (1989). Sensory Characterization of Human Milk. *J. of*
428 *Dairy Sci.*, 72(5), 1149-1158.
- 429 Sokal, D. C., Gerrard, S. E., Kneen, E., Hubbard, R., Galgon, G., & Banda, T. (2013). (12) United States
430 Patent, 2(12), 0–12.

- 431 Szakonyi, G., & Zelkó, R. (2013). Prediction of oral disintegration time of fast disintegrating tablets
432 using texture analyzer and computational optimization. *Int. J. of Pharm.*, 448(2), 346–53.
433 doi:10.1016/j.ijpharm.2013.03.047
- 434 U.S. Department of Health and Human Services. (2008). Guidance for Industry Orally Disintegrating
435 Tablets Guidance for Industry Orally Disintegrating Tablets. Retrieved from
436 [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070578.pdf)
437 [/ucm070578.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070578.pdf)
- 438 U.S. Pharmacopeial Convention. (2014a). <701> Disintegration. Retrieved from
439 <http://www.uspnf.com/uspnf/pub/index?usp=37&nf=32&s=0&officialOn=May 1, 2014>
- 440 U.S. Pharmacopeial Convention. (2014b). <1217> Tablet Breaking Force. Retrieved from
441 <http://www.uspnf.com/uspnf/pub/index?usp=37&nf=32&s=2&officialOn=December 1, 2014>
- 442 UNICEF. (2013). Dispersible Tablets. UNICEF. Retrieved from
443 http://www.unicef.org/supply/index_53571.html
- 444 Wang, C. D., Chu, P. S., Mellen, B. G., & Shenai, J. P. (1999). Creamatocrit and the Nutrient
445 Composition of Human Milk. *J. of Perinatol.*, 19(5), 343–346.

446

447 **Figure Captions**

448 Figure 1. An illustration of the Nipple Shield Delivery System (NSDS) during use delivering an active
449 pharmaceutical ingredient (API) into an infant during breastfeeding – provided courtesy of
450 justmilk.org.

451 Figure 2. Illustrations of Experimental Setup. (a) Demonstration of the attachment of the tablet in a
452 vertical orientation to the texture analyser probe. (b) Platform diagram (2)

453 Figure 3. Texture analyser probe data from the point of tablet contact with the platform for a single
454 trial of a SRB tablet disintegrating in water. The initial, ascending and plateau regions are labeled I, A,
455 and P, respectively, as based on the labeling conventions of Abdelbary et al.. (a) Position data. (b)
456 Position data overlaid with load data.

457 Figure 4. Texture analyser probe data from the point of tablet contact with the platform for a single
458 trial of a Sybedia Flashtab placebo tablet disintegrating in human milk. The initial, ascending and
459 plateau regions are labeled I, A, and P, respectively, as based on the labeling conventions of
460 Abdelbary et al.. (a) Position data. (b) Position data overlaid with load data.

461 Figure 5. Probe position data during texture analysis disintegration testing from the point of tablet to
462 platform contact. (a) SRB tablets and (b) Sybedia Flashtab placebo tablets in (i) Water, (ii) Bovine
463 Milk, and (iii) Human Milk. Calculated disintegration end points are shown as white circles (o).

Table 1
Laboratory-manufactured tablet composition.

Chemical	Role	w/w	Grade	Manufacturer
Sulforhodamine B (Sigma)	Model compound	2.6	75% Purity	Sigma-Aldrich, Dorset, UK
Lactose (SuperTab 14SD)	Filler	91.4	Ph. Eur	DFE Pharma, Goch, Germany
Sodium starch glycolate (Explotab CLV)	Superdisintegrant	3.0	Typ (A) Ph. Eur	Mendell GmbH, Volklingen, Germany
Croscarmellose sodium (Ac-Di-Sol)	Superdisintegrant	2.0	Ph. Eur	FMC Biopolymer, Girvan, UK
Magnesium stearate	Lubricant	1.0	Technical Grade	Sigma-Aldrich, Dorset, UK

Table 2

Physical characteristics of orally disintegrating tablets using United States Pharmacopoeia methods.

Tablet	SRB tablets		Sybedia Flashtab placebo tablets	
	Laboratory-manufactured		Ethypharm	
Manufacturer	Average \pm standard deviation	n	Average \pm standard deviation	n
Height (mm)	4.52 \pm 0.08	10	2.09 \pm 0.06	10
Width (mm)	5.98 \pm 0.02	10	3.69 \pm 0.02	10
Diameter (mm)	8.088 \pm 0.004	10	8.147 \pm 0.006	10
Weight (mg)	330 \pm 1	10	150 \pm 2	10
Hardness (N)	39 \pm 3	10	23 \pm 1	10
Tensile Strength (MPa)	0.53 \pm 0.04	10	0.50 \pm 0.03	10
Disintegration time (s)	30 \pm 2	6	23 \pm 2	6


n: number of samples; tensile strength was calculated assuming right cylindrical tablet geometry (U.S. Pharmacopeial Convention, 2014b)

Table 3
Average disintegration times for each tablet in various media using texture analysis disintegration testing.


	SRB tablets		Sybedia Flashtab placebo tablets	
	Average disintegration time (s) \pm standard deviation	n	Average disintegration time (s) \pm standard deviation	n
Water	82 \pm 7	8	23 \pm 4	5
Bovine milk	336 \pm 2	3	88 \pm 7	5
Human milk	122 \pm 9	4	81 \pm 4	5

n: number of samples

Figure(1)




Figure(1) (Colour)




Figure(2)


a



b




Figure(3)




Figure(4)

a



b



Figure(5)

